Array melanoma drugs show significant survival versus Roche drug in study

(Reuters) – A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.


Source: Reuters Health